Close Menu

Goldman Sachs

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

The downgrades to Illumina and Waters reflect larger worries the investment bank has about the end markets of life science tools firms.

In a research note, the investment house cited concerns about Cepheid's high price-to-sale ratio but said that the firm's installed base is expected to grow 27 percent year over year in 2011.

A report on Goldman Sachs' evaluations of Illumina and Life Technologies' desktop next-generation sequencing platforms once again was the most-read story on GWDN during the past week.

The investment firm lowered EPS estimates for Illumina on an expected shift to the MiSeq platform from the HiSeq system, but said that in a short amount of time Illumina's desktop sequencer would overtake Ion Torrent's PGM as the market leader.

Though Illumina has been predicting a second round of association studies run on chips containing rare variant content, CEO Jay Flatley said that the market is "at the very beginning" of this new phase, which Illumina refers to as "rich GWAS."

Pages

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.